Transcription factor RUNX3 is inactivated in a number of malignancies, including breast cancer, and is suggested to function as a tumor suppressor. How RUNX3 functions as a tumor suppressor in breast cancer remains undefined. Here, we show that about 20% of female Runx3 þ /À mice spontaneously developed ductal carcinoma at an average age of 14.5 months. Additionally, RUNX3 inhibits the estrogen-dependent proliferation and transformation potential of ERa-positive MCF-7 breast cancer cells in liquid culture and in soft agar and suppresses the tumorigenicity of MCF-7 cells in severe combined immunodeficiency mice. Furthermore, RUNX3 inhibits ERa-dependent transactivation by reducing the stability of ERa. Consistent with its ability to regulate the levels of ERa, expression of RUNX3 inversely correlates with the expression of ERa in breast cancer cell lines, human breast cancer tissues and Runx3 þ /À mouse mammary tumors. By destabilizing ERa, RUNX3 acts as a novel tumor suppressor in breast cancer.
Introduction
Breast carcinoma is a leading female malignancy and cause of cancer death in developed countries. Estrogen plays a critical role in normal mammary gland development and is also involved in the pathogenesis of breast cancer (LaMarca and Rosen, 2007) . The actions of estrogen are mediated by estrogen receptors a and b. ERa functions as a transcriptional regulator, stimulating proliferation and suppressing apoptosis through the regulation of genes involved in the cell cycle and apoptosis (Katzenellenbogen and Katzenellenbogen, 2000) . Abnormal estrogen signaling through ERa is associated with initiation and progression of breast cancer (Cheskis et al., 2007) . ERa is overexpressed in about 75% of breast cancers (Katzenellenbogen and Katzenellenbogen, 2000) . Deregulated ERa expression in mammary epithelial cells leads to the development of ductal carcinoma in situ (Frech et al., 2005) . Therefore, tight control of the level of ERa is important in maintaining normal estrogen responsiveness. Proteasome-mediated degradation of ERa plays an important role in regulating ERa function by controlling its cellular levels (Nawaz et al., 1999; Fan et al., 2004; Tateishi et al., 2004; Duong et al., 2007) .
RUNX3 belongs to the Runt-related gene family, whose members are all developmental regulators and have been shown to be involved in carcinogenesis (Ito, 2004) . The Runx3 gene is located in 1p36, a region often deleted in a wide variety of human carcinomas, including breast cancer. A possible role for RUNX3 as a tumor suppressor in breast cancer is suggested by its frequent inactivation by protein mislocalization and promoter hypermethylation in breast cancer cell lines and breast cancer tissues, and this inactivation constitutes an early event in breast cancer progression (Lau et al., 2006; Jiang et al., 2008; Subramaniam et al., 2009a) . Furthermore, expression of RUNX3 is associated with a more favorable prognosis in breast cancer patients, and RUNX3 expression generally decreases during breast cancer progression (Jiang et al., 2008) . In female mice, loss of Runx3 affects ovulation and estrogen-induced endometrial cell proliferation (Sakuma et al., 2008) . These studies highlight RUNX3's potential role as a tumor suppressor in breast cancer. However, there is no direct evidence that RUNX3 functions as a tumor suppressor in breast cancer and a plausible mechanism by which RUNX3 could act as a breast cancer tumor suppressor has not been described.
Here, we report that Runx3 þ /À female mice spontaneously develop mammary ductal carcinoma. Expression of RUNX3 suppresses estrogen-dependent proliferation and tumorigenesis of ERa-positive MCF-7 cells.
Furthermore, RUNX3 inhibits the transcriptional activation of ERa by inducing its proteasome-mediated degradation. These data suggest that RUNX3 functions as a tumor suppressor in breast cancer by regulating the stability of ERa.
Results and discussion
Disruption of Runx3 led to the development of ductal adenocarcinoma in mammary gland epithelium While maintaining Runx3 þ /À mice, we observed that some female mice developed abnormalities in the mammary gland after a year. About one-fifth (11 of 52 (21.2%)) of the Runx3 þ /À female mice developed mammary tumors at the age of 15 months whereas none of the 32 wild-type (WT) mice developed mammary tumors at this age ( Figure 1A ). The tumors in the mice ranged from 10 mm to 20 mm in diameter and all the primary tumors were relatively well differentiated. Histochemical staining revealed that these spontaneous tumors were ductal adenocarcinoma with solid pattern of growth ( Figure 1B , e and f). In these Runx3 þ /À tumors, expression of RUNX3 was markedly reduced ( Figure 1B , g and h) compared with the highly expressed RUNX3 in the mammary gland epithelial cells of the WT mice ( Figure 1B, c and d) .
Examining the proliferation marker Ki-67 revealed that Ki-67 was quite abundant in the Runx3 þ /À tumors whereas Ki-67 levels were significantly lower in the mammary gland epithelial cells of WT mice ( Figure 1C ). These data suggest that the mammary tumors in Runx3 þ /À mice are due to increased proliferation and that RUNX3 might act as a tumor suppressor by inhibiting mammary gland epithelial cell proliferation.
To further characterize these Runx3 þ /À tumors, we examined the expression of ERa, PR (progesterone receptor) and Her2/neu (human epidermal growth factor receptor 2), three different prognostic biomarkers of breast cancer. In the mammary gland epithelial cells of the WT mice, the expression of ERa, PR and Her2/ neu was low and barely detectable ( Figure 1D and Supplementary Figure S1) . Interestingly, the expression of ERa was significantly enhanced in Runx3 þ /À tumors ( Figures 1D, c and d) , while the expression of PR was moderately increased and the expression of Her2/neu remained the same compared with WT mice (Supplementary Figure S1 ). As ERa regulates the expression of PR (Anderson, 2002) , the enhanced PR expression might result from the enhanced expression of ERa. Therefore, these Runx3 þ /À tumors are ERa positive and likely PR positive, but are Her2/neu negative.
RUNX3 inhibits the proliferation and tumorigenesis of MCF-7 cells As Runx3 þ /À tumors are ERa positive and excessive signaling through ERa has been shown to be the primary mechanism for breast tumorigenesis (Jerry et al., 2010) , we hypothesized that RUNX3 might target ERa signaling for its tumor suppressor function. To test this hypothesis, we examined the effect of RUNX3 on the proliferation of an ERa-positive MCF-7 cell line. As RUNX3 is not expressed in MCF-7 cells due to hypermethylation of the Runx3 promoter (Lau et al., 2006) , we re-introduced RUNX3 into MCF-7 cells using a retroviral expression vector and generated MCF-7 cells stably expressing RUNX3 (designated RUNX3-MCF-7). Vector-MCF-7 and RUNX3-MCF-7 cells exhibited very slow growth over 3 days without 17b-estradiol (E 2 ) (Figure 2a) . The vector-MCF-7 cells started to grow quickly when E 2 was added to the media at day 3 (Figure 2a ). In contrast, the growth of RUNX3-MCF-7 cells was significantly reduced in the presence of E 2 compared with the vector-MCF-7 cells (Figure 2a ) and the reduced growth of RUNX3-MCF-7 cells was not due to increased cell death (Supplementary Figure S2) . Together, these data suggest that RUNX3 inhibits estrogen-dependent proliferation of MCF-7 cells.
Next, we investigated the effect of RUNX3 on the transformation potential of MCF-7 cells by anchorageindependent growth assay. As expected, vector-MCF-7 cells formed colonies in soft agar ( Figure 2b ). Conversely, both the number and size of the colonies formed by the RUNX3-MCF-7 cells were significantly reduced (Figure 2b ), indicating that RUNX3 impairs the transformation potential of MCF-7 cells.
We then determined the effect of RUNX3 expression on breast cancer formation and growth in an animal model. Compared with vector-MCF-7 cells, RUNX3-MCF-7 cells produced smaller tumors in severe combined immunodeficiency mice ( Figure 2c ). The average weight of the tumors formed by the RUNX3-MCF-7 cells was o80%, lower than those formed by the vector-MCF-7 cells (Figure 2d ). These results indicate that RUNX3 inhibits the ability of ERa-positive breast cancer cells to grow as tumors.
RUNX3 inhibits the transcriptional activity of ERa As RUNX3 inhibits E 2 -dependent proliferation and tumorigenesis of MCF-7 cells ( Figure 2 ) and ERa plays a key role in mediating the action of estrogen, we next examined the effect of RUNX3 on the activity of ERa. MCF-7 cells were transfected with RUNX3 expression vector and a reporter plasmid containing four copies of the estrogen response element (ERE). Co-expression of RUNX3 inhibited basal as well as E 2 -activated ERE reporter activity ( Figure 3a , left panel). Conversely, RUNX3 had no effect on the luciferase reporter activity when the ERE sites were deleted (Supplementary Figure  S3) , suggesting a direct effect of RUNX3 on ERa. Similarly, RUNX3 inhibited the basal and E 2 -activated PI-9 promoter-driven luciferase reporter activity in both MCF-7 cells and normal mammary epithelial cells (Figure 3a , right panel and Supplementary Figure S4) , ruling out the possibility that the inhibitory response reflects a selective inhibition of the 4 Â ERE reporter in cancer cells.
When we assessed the effect of RUNX3 on the expression of ERa target genes, we found that E 2 -stimulated expression of two ERa-responsive genes, pS2 and NRIP1, was significantly reduced in the RUNX3- þ /À BALB/c mice was described previously . The mice were maintained in pathogen-free conditions and monitored daily. All procedures involving animals were performed in accordance with the guidelines of Nagasaki University Animal Care and Use Committee. (B) Mammary gland specimens from wild-type and Runx3 þ /À BALB/c mice were fixed with 4% paraformaldehyde in phosphate-buffered saline, embedded in paraffin and sectioned at 4 mm. Sections were stained with hematoxylin and eosin (HE). HE sections were evaluated by a pathologist (M.S.-T.). Representative HE staining and RUNX3-immunohistochemical staining of a normal mammary gland from a WT mouse (left four panels, a-d) and an adenocarcinoma of mammary gland from a Runx3 þ /À mouse (right four panels, e-h) are shown. Boxed regions are enlarged to the right of each image. Scale bars: 100 (lower magnification) and 50 (higher magnification) mm. (C, D) Immunohistochemical staining of Ki-67 (C) and ERa (D) in serial sections from (B). For the detection of RUNX3, Ki-67 and ERa protein expression, rehydrated specimens were treated for 40 min at 96 1C with an antigen retrieval solution (S1700; DAKO). The specimens were incubated with antibodies against RUNX3 (R3-3F12 as previously described (Ito et al., 2009) ), Ki-67 (M7249; DAKO) or ERa (SC-542; Santa Cruz Biotech, Santa Cruz, CA, USA). The EnVision þ system (DAKO, Carpineria, CA, USA) was used for visualization of signals in (B)-(D).
RUNX3 downregulates estrogen receptor a B Huang et al RUNX3 were observed in another ERa-positive breast cancer cell line, T47D (Supplementary Figure S5) , further confirming that RUNX3 negatively regulates the activity of ERa. To further confirm the inhibitory effect of RUNX3, we knocked down the expression of RUNX3 using small interfering RNA in MDA-MB-361 cells, which express both RUNX3 and ERa. Depletion of RUNX3 enhanced the E 2 -induced expression of both pS2 and NRIP1 genes (Figure 3c) . Consistent with the decreased expression of ERa in RUNX3-MCF-7 and RUNX3-T47D cells (Figure 3b and Supplementary Figure S5) , depletion of RUNX3 resulted in an increased level of ERa (Figure 3c ). These data, together with the data from the Runx3 þ /À mice ( Figure 1D ), indicate that RUNX3 downregulates the level of ERa.
RUNX3 induces the proteasome-mediated degradation of ERa
To further explore the possible relationship between the expression levels of ERa and RUNX3, we examined the expression of RUNX3 and ERa in a panel of cell lines including non-tumorigenic breast epithelial cells and breast cancer cell lines. Although the levels of ERa vary in different cell lines (Figure 4A ), the overall expression of ERa appeared to be inversely correlated with the expression of RUNX3 ( Figure 4A ). Furthermore, when we examined the possible pathological relationship of the expression of RUNX3 and ERa in human normal breast and breast cancer samples, we also observed a close inverse correlation between the expression of RUNX3 and ERa ( Figure 4B ). Importantly, when we examined the expression of RUNX3 and ERa in a cohort of 80 human breast ductal carcinoma samples, we observed that 70% of samples (16 out of 23) with low expression of RUNX3 displayed high expression of ERa ( Figure 4C ). Conversely, 65% of samples (37 out of 57) with high expression of RUNX3 had low levels of ERa. Statistical analysis reveals an inverse correlation between the expression of RUNX3 and ERa in these cancer samples with a Spearman coefficient for correlation (RUNX3 and ERa) of À0.314 (P ¼ 0.005) ( Figure 4C ). and then plated in 6-well plates coated with an initial underlay of 0.5% SELECT Agar (Invitrogen) in culture medium. Colony growth was scored after 14 days of cell incubation at the normal condition. Representative photographs were taken at day 1 and day 14 to show colonies. All the colony formation assays presented in this study were repeated in at least three independent experiments. (c) Six-week-old female severe combined immunodeficient (SCID) mice (C.B-17/IcrCrl-scidBR) (Charles River Laboratories, Wilmington, MA, USA) were subcutaneously implanted with a slow release pellet of 25 mg E 2 . Four days later, the mice were injected in the inguinal mammary fat pads with vector-MCF-7 or RUNX3-MCF-7 stable cell lines (5 Â 10 6 ). The recipient mice were monitored daily by palpation, and killed and dissected for tumor evaluation 30 days post-injection. Pictures were taken at day 30 after cell inoculation. Mouse injection was performed essentially as previously described (Yan et al., 2009) . All experiments involving mice were approved by the Institutional Animal Care and Use Committee (IACUC). (d) Summary of the average weight of tumors from (c). Data represent mean ± s.e.m. (n ¼ 3). *:Po0.05 (paired t test).
RUNX3 downregulates estrogen receptor a B Huang et al
The inverse relationship between ERa and RUNX3 expression prompted us to investigate whether RUNX3 might regulate ERa stability. We transfected increasing amounts of RUNX3 into MCF-7 cells and examined the effect of RUNX3 on the expression of endogenous ERa. Expression of increasing levels of RUNX3 decreased the levels of endogenous ERa in a dose-dependent manner ( Figure 4D ). The decreased expression of endogenous ERa was reversed by treatment with proteasome inhibitor MG-132 ( Figure 4D ), and RUNX3 had no effect on the level of ERa mRNA (Supplementary Figure S6) , suggesting that RUNX3 reduces the expression of ERa at the protein level rather than at the mRNA level and that RUNX3 regulates the stability of ERa.
To more quantitatively evaluate the effect of RUNX3 on the stability of ERa, we compared the half-life of endogenous ERa in the absence and presence of RUNX3 using vector-MCF-7 and RUNX3-MCF-7 cells. We performed the pulse-chase experiment using 35 S-methionine to label endogenous ERa or cycloheximide to inhibit the synthesis of new ERa ( Figure 4E and Supplementary Figure S7) . The levels of ERa gradually decreased in vector-MCF-7 cells and ERa was RUNX3 downregulates estrogen receptor a B Huang et al relatively stable in the absence of RUNX3 with a halflife of about 6 h ( Figure 4E , right panel, and Supplementary S7). However, in RUNX3-MCF-7 cells, the degradation of ERa was accelerated and the half-life of ERa was reduced to about 2 h ( Figure 4E , right panel and Supplementary Figure S7 ). Importantly, RUNX3 had no effect on the half-life of Her2/neu (Supplementary Figure S8 ), indicating a specific effect of RUNX3 on ERa stability. Together, these findings demonstrate that RUNX3 reduces the stability of ERa by inducing its proteasome-mediated degradation. Inactivation of RUNX3 by protein mislocalization and hypermethylation of the Runx3 promoter is often found in breast cancer cells and breast tumors (Subramaniam et al., 2009b) , suggesting a tumor suppressor function of RUNX3 in breast cancer. However, there is no clear and direct evidence for its tumor suppressor activity in breast cancer. Here, we demonstrate that Runx3 þ /À mice developed spontaneous mammary tumors (Figure 1 ), supporting the notion that RUNX3 is a tumor suppressor in breast cancer. Moreover, we show that RUNX3 elicits its tumor suppressor activity by targeting ERa signaling. RUNX3 inhibits ERa activity by inducing the proteolytic degradation of ERa (Figures 3 and 4) .
It has been well documented that ubiquitination and degradation of ERa regulate ERa activity. Ubiquitination and degradation of ligand-bound ERa and its coactivators have been shown to be involved in the transcriptional activation or inactivation of ERa, depending on the experimental conditions (Nawaz et al., 1999; Lonard et al., 2000; Reid et al., 2003; Fan et al., 2004) . Nevertheless, ubiquitination and degradation of ligand-free receptor has a clear role in The detection of the expression of RUNX3 and ERa of the human tissue microarray was performed as previously described (Zhang et al., 2003) . (C) Tissue sections of 80 breast cancer samples were immunostained with anti-RUNX3 or anti-ERa antibodies for the expression of RUNX3 and ERa and their correlation was analyzed by Sperman rank correlation test (P ¼ 0.005). RUNX3 staining intensity was graded as previously described with a score 0 to 3 (Subramaniam et al., 2009a) . Samples with a score 0 or 1 were graded as low, samples with a score 2 or 3 were graded as high. For ERa, staining occurred in more than 50% of tumor cells was graded as high whereas staining occurred in less than 50% of tumor cells was graded as low (Zhang et al., 2003) . (D) MCF-7 cells were transfected with increasing amounts of Myc-RUNX3 as indicated. Forty-two hours post-transfection, cells were treated with vehicle or MG-132 (20 mM) for 6 h, and whole cell lysates were immunoblotted as indicated. (E) Vector-MCF-7 and RUNX3-MCF-7 cells were plated in 6 cm dishes. Twenty-four hours later, cells were incubated with Dulbecco's modified Eagle's medium (DMEM) lacking methionine and cysteine (Invitrogen) for 1 h, and then labeled with 35 S-methionine (PerkinElmer) in a final concentration of 20 mCi/ml for 1 h. The media was replaced with DMEM and cells were cultured (chased) for indicated time points. ERa was immunoprecipitated using an anti-ERa antibody and separated on SDSpolyacrylamide gel electrophoresis gel. 35 S-labeled ERa was detected by autoradiography. Representative gels are shown in the left panel. Quantification of the results from three independent experiments is shown in the right panel.
RUNX3 downregulates estrogen receptor a B Huang et al downregulating the basal levels of ERa (Fan et al., 2004; Tateishi et al., 2004; Duong et al., 2007) . Although RUNX3 inhibits the transcriptional activity of ERa by inducing its degradation in the presence of E 2 ( Figure 3 and Supplementary Figure S9 ), it appears that degradation of ERa by RUNX3 could be ligand-independent preceding the binding of ERa to DNA as RUNX3 inhibits the basal ERa activity and degrades ERa in the absence of E 2 (Figure 3 and Supplementary Figure S9) . Consistent with this notion, RUNX3 induced the degradation of a ligand-binding-deficient mutant of ERa (ERa-L525A) (Ekena et al., 1996) to the same level as WT ERa (Supplementary Figure S10) . Currently, it is unclear how RUNX3 induces the degradation of ERa. But it appears that the transcriptional activity of RUNX3 is not essential for the degradation as a transcriptionally incompetent mutant of RUNX3, RUNX3-R122C (Chi et al., 2005) was still able to induce the degradation of ERa (Supplementary Figure  S11) . It is possible that RUNX3 might recruit an E3 ubiquitin ligase or directly function as an E3 ubiquitin ligase for the ubiquitination and degradation of ERa, but the detailed molecular mechanism needs to be further explored. Our data define a role for RUNX3 as a tumor suppressor in ERa-positive breast cancers and show that the expression of ERa and RUNX3 display an inverse correlation in ERa-positive cancer cells ( Figure 4A ). However, it has to be noted that expression of RUNX3 is also downregulated in some ERa-negative breast cancer cells like MDA-MB-231 and that RUNX3 might also exert tumor suppressor activity in these breast cancer cells (Lau et al., 2006) . Although the mechanism remains unknown, in ERa-negative MDA-MB-231 cells, RUNX3 reduced the invasiveness and tumorforming potential of these cells (Lau et al., 2006) , indicating a tumor suppressor role for RUNX3 in ERanegative breast cancer. Although downregulation of the stability of ERa by RUNX3 likely is the major factor in its tumor suppressor activity in ERa-positive cancer cells, in ERa-negative cancer cells RUNX3 might cooperate with other transcription factors, such as FOXO3a or receptor-regulated Smads, to induce apoptosis by activating pro-apoptotic genes (Yamamura et al., 2006; Yano et al., 2006) . Thus, it is likely that RUNX3, using different mechanisms, possesses tumor suppressor activity in both ERa-positive and -negative breast cancers.
Enhanced ERa expression in normal breast epithelium is associated with increased risk of breast cancer (Khan et al., 1994; Shoker et al., 2000) . RUNX3 might function as a 'gate-keeper' and play a role in the onset of breast cancer by controlling the response to circulating estrogens through regulation of the cellular level of ERa. Inactivation of RUNX3 results in increased stability of ERa and enhanced cell proliferation in response to circulating estrogens. As RUNX3 is frequently inactivated in primary breast tumors, restoring RUNX3 expression represents an attractive new therapeutic target with potential for treatment of ERapositive breast cancer.
